CompletedPhase 2NCT03648489
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
Studying Primary peritoneal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Imperial College London
- Principal Investigator
- Jonathan Krell, DDSImperial College London
- Intervention
- Paclitaxel(drug)
- Enrollment
- 134 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2018 – 2023
Study locations (15)
- Charité Universitätsmedizin Berlin, Berlin, Germany
- Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany
- KEM Kliniken Essen-Mitte, Essen, Germany
- Furness General Hospital, Barrow in Furness, Cumbria, United Kingdom
- St George's University Hospitals NHS Foundation Trust, London, Greater London, United Kingdom
- The Royal Marsden NHS Foundation Trust, London, Greater London, United Kingdom
- Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom
- The Royal Marsden NHS Foundation Trust, Sutton, Greater London, United Kingdom
- The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
- Royal Lancaster Infirmary, Lancaster, Lancashire, United Kingdom
- Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
- Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom
- Churchill Hospital, Oxford, United Kingdom
- Weston Park Hospital, Sheffield, United Kingdom
- Southampton General Hospital, Southampton, United Kingdom
Collaborators
Takeda Pharmaceuticals International, Inc. · North Eastern German Society of Gynaecological Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03648489 on ClinicalTrials.govOther trials for Primary peritoneal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07480954Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07322094CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerTORL Biotherapeutics, LLC
- RECRUITINGPHASE3NCT06915025Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerImunon
- RECRUITINGPHASE2NCT07023484Personalized Timing of Interval Debulking Surgery in Advanced Ovarian CancerThe University of Hong Kong
- RECRUITINGPHASE2NCT06639074Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT TrialMayo Clinic
- RECRUITINGPHASE1NCT06469281A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRegeneron Pharmaceuticals
- RECRUITINGPHASE2NCT06492070Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersEmory University
- RECRUITINGPHASE2NCT06434610A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Shanghai Jiaolian Drug Research and Development Co., Ltd